FOLH1 and metastatic neoplasm: Owing to a lower prevalence of PSMA-PET–evident localized or distant metastatic disease at lower PSA values, the base case analysis estimated a lower absolute benefit to imaging; however, improvements in outcomes were still anticipated in patients with PSA less than 2.00 ng/mL.